第十一批国家组织药品集采报量启动

Core Points - The National Drug Procurement Office has initiated the 11th batch of centralized drug procurement, with a demand reporting period from August 6 to 25, 2023 [1] - A total of 480 companies submitted drug information, with an average of 15 companies per drug type among the 55 proposed procurement varieties [1] - The procurement process allows medical institutions to report demand based on generic names or specific brands, encouraging participation from recognized companies [1][2] - Medical institutions are required to report demand accurately, with a minimum annual demand of 80% of the average usage for 2023-2024 [1] - The reporting system accommodates basic drugs and pediatric medications, allowing institutions to determine conversion ratios if necessary [2] - The National Healthcare Security Administration clarified that while institutions should prioritize selected drugs, they are not restricted to only using them, with 60%-80% of reported demand typically covered by selected drugs [3] - Historical data indicates that over 80% of institutions continue to use selected drugs even after fulfilling their procurement agreements [3] Summary by Sections Procurement Process - The 11th batch of centralized drug procurement is being organized, with a focus on accurate demand reporting from medical institutions [1] - 480 companies have submitted relevant drug information, indicating a competitive environment for the procurement process [1] Reporting Requirements - Medical institutions can report demand based on generic names or specific brands, enhancing flexibility in the procurement process [1][2] - Institutions must report a minimum of 80% of the average annual usage for the upcoming years, ensuring realistic demand assessments [1] Policy Clarifications - The procurement policy allows for adjustments based on clinical needs, particularly for basic and pediatric medications [2] - Institutions are encouraged to prioritize selected drugs but are permitted to procure non-selected drugs as needed, reflecting a balanced approach to drug availability [3]